AeroImmune Biotechnolgies Brian Lichty Inhaled vaccines and anti-virals. Current programs include two candidate next-gen, inhaled multi- antigen COVID19 vaccines, an inhaled multi-antigen TB vaccine (that targets each life stage of TB infections) as we'll as candidate, inhaled pan-influenza vaccines. Contact: Brian Lichty <lichtyb@mcmaster.ca>; Fiona Smaill <smaill@mcmaster.ca>
AmacaThera Inc Mike Foorer *amacathera.ca* AmacaThera is a clinical-stage company transforming therapeutics to make a difference in patient health. AmacaGel™, our unique, injectable hydrogel platform provides localized sustained drug delivery for improved patient outcomes across multiple therapeutic areas, including post-surgical pain management, cancer and other hard-to-reach unmet medical needs. Contact: Mike Foorer <mike_foorer@amacathera.ca>
Ampa Health Jonathan Downar *ampahealth.com* Transcranial Magnetic Stimulation (TMS) is a Health Canada-approved, non-invasive brain stimulation treatment used for depression and increasingly for other psychiatric and neurological conditions, with the most recent treatment protocols now offering high remission rates (~70-80%) and rapid effect (5 days to remission). While TMS is currently delivered in clinics by specialized staff, Ampa Health has developed a next-generation, portable TMS device suitable for deployment via telemedicine in remote or home settings, for populations who cannot easily attend clinics, such as late-stage palliative care patients, or patients with dementia or movement disorders. Contact: Jonathan Downar <jonathan.downar@ampahealth.com>
Anatomiz3D Healthcare Limited Firoza Kothari *anatomiz3d.ca* Anatomiz3D provides 3D Printed patient specific anatomical models, custom cutting and drilling guides and implants from patient CT and MRI scans. It also sets up Point of Care labs, allowing in-house hospital lab set-ups run by Anatomiz3D and provides defect based education models for students to practice complex surgeries. Contact: Firoza Kothari <firoza@anatomiz3d.com>

Presenters and Exhibitors
Arterial Solutions Mohammad Qadura *entrepreneurs.utoronto.ca/startup/arterial-solutions/* Arterial Solutions is a medical device company that aims to introduce novel diagnostics for a variety of cardiovascular diseases. Our first product, Artery Alert, is the first-ever blood test for peripheral arterial disease (PAD). This test will help physicians diagnose PAD in a timely manner, improve the quality of life of patients, and significantly curtail healthcare expenditure. Contact: Mohammad Qadura <mohammad.qadura@utoronto.ca>
Aufero Medical Daniel Gelman Aufero Medical's catheter stabilizing technology will improve the effectiveness of atrial fibrillation ablation therapy. Our unique, plug-n-play accessory device attaches easily to commonly used ablation catheters and provides on-demand contact stability. Designed with electrophysiologists, our product is intuitive, user-friendly, and has minimal impact on regular procedure workflows, making it an essential addition to any EP catheter lab. Contact: Daniel Gelman <dgelman@auferomedical.com>
Bay Area Research Logistics Kaitlin Guarasci *bayarearesearchlogistics.com* Finding a supply chain solution that is right for your clinical trial can be a challenge and will likely not get simpler any time soon. This presentation will highlight at a high-level what goes into planning for and delivering a study drug, given the global reach of today's clinical trials. Consequently, it is important to be aware of some common elements associated with outsourcing to decrease risk and increase success when partnering with a logistics partner. Contact: Kaitlin Guarasci <guarascik@barl.ca>
Bold Therapeutics Inc. Michelle Jones *bold-therapeutics.com* Bold Therapeutics is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia founded to develop and commercialize BOLD-100, a first-in-class metallotherapeutic being developed for the treatment of advanced cancers. BOLD-100 is the most clinically advanced ruthenium-based therapeutic in development and is currently being studied in a global Phase 2 trial for the treatment of patients with advanced gastrointestinal cancers. Bold Therapeutics is now embarking on a Canadian-led clinical trial evaluating BOLD-100 in combination with standard of care for advanced sarcomas. Contact: Jim Pankovich <jp@bold-therapeutics.com>; Michelle Jones <clinical@bold-therapeutics.com>
Canurta Akeem Gardner *canurta.com* Canurta is a preclinical biotechnology company pioneering the discovery and production of novel, polyphenol-rich ingredients to improve chronic disease prevention and recovery for humans and animals. Our ingredients enhance the functionality of foods, wellness products and biopharmaceuticals. Contact: Akeem Gardner <akeem@canurta.com>

Presenters and Exhibitors
CardioSTAT by Icentia Michele Bischof *cardiostat.com* A turnkey ECG monitoring solution from end to end delivering high-quality results while streamlining workflow. CardioSTAT solution offers complete flexibility for decentralized and hybrid clinical trials to lower cost and improve patient enrolment. Contact: Dany Grondin <dany.grondin@icentia.com>; Michele Bischof <michele.bischof@icentia.com>
Cloud DX Inc. Neil Fraser *clouddx.com* Cloud DX supplies a complete Remote Patient Monitoring, Virtual Care Platform that connects patients to the care continuum from home. The Connected Health Platform by Cloud DX is able to monitor patient vital signs both episodically and continuously, facilitate questionnaires, drive patient engagement and conduct virtual visits by privacy-compliant chat and video. Published studies have shown that remote automated monitoring (RAM) with Connected Health improves patient outcomes and reduces ER visits and hospital admissions. Contact: Anthony Kaul <Anthony.kaul@clouddx.com>; Neil Fraser <neildavidfraser@gmail.com>
Cosm Medical Goli Ameri *cosm.care* Cosm is a VC-backed medical device start-up in Toronto, developing a data-driven platform to create a personalized treatment for female pelvic floor disorders, which affect up to 50% of the female population. Cosm's platform leverages a novel medical imaging technique based on ultrasound imaging, as well as machine learning and 3D printing to address the needs of this underserved patient population. Since its inception in 2018, Cosm has grown from a team of 2 to 18 and is still expanding. Contact: Goli Ameri <gameri@cosm.care>
Cytokinetics Richey Neuman *cytokinetics.com* Cytokinetics develops potential medicines to improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function, like heart failure, hypertrophic cardiomyopathy (HCM), and amyotrophic lateral sclerosis (ALS). By focusing on impacting the mechanics of muscle with investigational medicines that may improve strength, power, or performance, we aspire to develop new treatment options that may dramatically improve the lives and functionality of people living with debilitating diseases. Contact: Richey Neuman <rneuman@cytokinetics.com>
Ensho Kaveh Katebian *enshohealth.com* Ensho Health provides on-demand analysis of EHR data for medical research and clinical care. Healthcare providers connect to our data lab through integrations with Epic, Cerner, Accuro, OscarPro and other major EMR systems. Once connected, they can request one-time or recurring analyses of structured and unstructured data to match patients with clinical trials, enroll in real world studies, and for clinical quality improvement initiatives including with proprietary diagnostic algorithms. Contact: Kaveh Katebian <kaveh.katebian@ensho.ai>

Presenters and Exhibitors
ex-able Lancy Qiu *ex-able.com* Limited evidence exists on the safety and accuracy of remote physical assessments in COPD which can result in delays to patients starting 'in-clinic' or tele-pulmonary rehabilitation (PR). Ex-able offers a high adherence platform that uses motion detection technology to aid the delivery of remote rehabilitation for chronic disease patients. Our focus is developing our technology to facilitate accurate remote assessment, allowing precise exercise prescription for COPD patients and a future predicting and preventing adverse events (e.g. falls) Contact: Rebecca Zucco <becky@willkin.ca>; Lancy Qiu < lancy.qiu@iwarehealth.com>
FluidAI Medical Nour Helwa *fluidai.md* FluidAI is a medtech startup that uses artificial intelligence to redefine postoperative care by utilizing the plethora of data within the body to enable data-driven intervention and care. Our first solution, Stream Platform™, makes use of novel sensors and machine learning algorithms to monitor patient recovery following gastrointestinal surgery, with the goal of early detection of complications such as postoperative leaks. Contact: Youssef Helwa <yhelwa@fluidai.md>; Nour Helwa <nhelwa@fluidai.md>
HelpWear Brian McQuaker *helpwear.ca* HelpWear builds a 24/7 continuous, clinical grade ECG from a monitor worn on the patient's bicep. HelpWear's technology removes barriers for monitoring with traditional holster platforms and invasive implant monitoring devices. Contact: Derek Exner <exner@ucalgary.ca>; Brian McQuaker <brian.mcquaker@helpwear.ca>
HOP Technologies Marc-Antoine Pelletier *hoptech.ca* As a digital health company, HOP TECH participates in numerous clinical trials through university hospitals and pharmaceutical company collaborative agreements. Marc-Antoine Pelletier, HOP TECH's CEO will be presenting a short presentation on DISCOVERY an end-to-end digital clinical trial platform for the development of indication specific algorithms. HOP TECH business expansion with other Canadian and international partners is focused towards projects that require AI pipeline capabilities to accelerate the execution of clinical trials in respiratory diseases, type2-diabetes and heart failure. Contact: Marc-Antoine Pelletier <mapelletier@hoptech.ca>
Information Mediary Corporation Joanne Watters *informationmediary.com* Including a smart packaging solution in your trial design may just be your number one cost-cutting decision to consider. Innovative designs are easily integrated into supply chains and provide real-time tracking of the investigational medicinal product (IMP). Efficiently managing drug supply and automating reconciliation processes are true end-to-end accountability measures that lead to improved patient safety. Contact: Nathan Petersen <npetersen@informationmediary.com>; Joanne Watters <jwatters@informationmediary.com>

Presenters and Exhibitors
JN Nova Pharma John Gillard *jnnova.com* Our lead therapeutic molecules are corona-viral neutralizing agents which trap and inhibit viral entry to the lungs and have full ACE2 enzyme replacement activity, supporting protection from acute kidney injury (AKI) and enhanced recovery from the acute respiratory syndrome (ARDS) and Pulmonary Fibrosis. Contact: Nathan Yoganathan <nathan@jnnova.com>
Kinarm Anne Vivian-Scott *kinarm.com* Kinarm is a solution to the lack of precision and consistency in neurological assessment. With over 20 years of use by neuroscientists and clinician scientists across more than two dozen indications (neuro and non-neuro), Kinarm Labs are proven to provide the sensitivity, precision and confidence to measure subtle changes in brain function and dysfunction. Such validation is essential to authoritatively confirm the effect of candidate therapeutics. Contact: Anne Vivian-Scott <avivianscott@kinarm.com>
Lumedi Inc. Frank Naus *Lumedi.org* Lumedi delivers data platforms that are secure, privacy compliant, scalable, customizable, and reliable. Lumedi's EDC platform is perfect for efficient clinical trial data collection and storage by sites and directly from participants. Lumedi's simple, powerful and collaborative solutions are utilized by industry for Patient Support Programs (PSP) and as part of a Learning Management Systems (LMS). Contact: Frank Naus <frank@lumedi.org>
Lumenix AIMS Jeremy Grimshaw *aimsplatform.io* Lumenix is a leading provider of hardware, software, sensors, and AI technologies driving innovation in healthcare. Our latest technology, the Artificially Intelligent Monitoring System (AIMS), is a multi-functional AI platform technology designed to solve some of healthcare's most persistent data, quality, patient safety and resource management issues. Contact: Jaimie Holland <jaimie.holland@lumenix.com>
Mind-Easy Dalia Ahmed *mind-easy.com* Culturally adapted and clinically validated self-help mental health solutions for diverse workforces. Contact: Alexandra Assouad <alexandra@mind-easy.com >; Dalia Ahmed <dalia@mind-easy.com>
Momentum Health Evan Dimentberg *momentum.health* Momentum Spine, Momentum Health's first product, is a double-ended telehealth application to connect scoliosis patients to their physician securely and remotely. The mobile application employs smartphone cameras to recreate a true-to-scale three-dimensional model of the desired region from a simple video. Momentum Spine quantifies extra-spinal deformities (what we see from the outside) and correlates them to the Cobb Angle (what we can only see on X-rays) to predict the progression of the deformity and optimize clinical workflows. Contact: Evan Dimentberg <evan@momentum.health>

Presenters and Exhibitors
Myant Inc. Bastien Moineau *myanthealth.com* Myant is a Toronto company developing technology and medical devices using Textile Computing, from fundamental materials research to cloud computing. Our first Class 2 Medical Device, Skiin, uses conductive yarns and miniaturized electronics to comfortably and remotely collect ECG and other health metrics. Contact: Milad Alizadeh-Meghrazi <miladam@myant.ca>; Bastien Moineau <bastien.moineau@myant.ca>
Noa Therapeutics Carla Spina *noatherapeutics.com* Noa Therapeutics is a preclinical biotech company leveraging a systems biology approach to accelerate the design of tailored multimodal solutions for complex inflammatory diseases. Leveraging their discrete expertise in skin and wound therapeutics, Noa's scientific entrepreneurial team are advancing a first-use case in Atopic Dermatitis. By simultaneously addressing three constructive therapeutic targets, Noa's multimodal therapies will address a range of unmet needs enabling expansion into applications for systemic inflammatory diseases. Contact: Carla Spina <carlaspina@noathera.com>
nVIGORus Steven Grover *Nvigorus.com* Estimating the risk of dementia can support shared decision making to engage high risk individuals to reduce their risk through targeted prevention strategies (both lifestyle and pharmacotherapy). Using artificial intelligence (AI), and UK Biobank data, we have developed a validated dementia risk assessment (AUC 85%) that does not require biometric tests, imaging, or clinical evaluations. The HealthyBrainAge calculator is currently being evaluated in a proof-of-concept study (Funded by Innovative Solutions Canada) to engage federal employees to reduce their dementia risk using an online health promotion program. Contact: Steven Grover <steven.grover@mcgill.ca>
PhysioBiometrics Inc. Nancy E. Mayo *physiobiometrics.com* PhysioBiometrics Inc. is a company dedicated to developing accessible technologies for people with movement vulnerabilities so they can move BETTER to move MORE. The pivotal technology is the Heel2ToeTM sensor that clips to the side of the shoe and provides real-time auditory feedback for a good step, one in which the gait cycle starts with a strong heel strike. Dopamine driven reward-feedback loop harnesses the power of the brain to stamp in a more normal gait cycle making walking better, faster, more efficient, and safer. Contact: Nancy E. Mayo <mayo@physiobiometrics.com>
Qidni Labs Morteza Ahmadi *qidni.life* Qidni Labs is making dialysis super accessible for patients with kidney failure. During our presentation, we will be covering our main product, Qidni/D, which is a nearly waterless, portable and cloud-enabled dialysis system that will enable patients to perform treatment anywhere at any time. We will also provide background on the progress the company has made to date and the exciting plans the company has for the future. Contact: Morteza Ahmadi <ma@qidni.com>

Presenters and Exhibitors
Qu Biologics Hal Gunn *qubiologics.com* Qu Biologics' novel immunomodulation platform is designed to restore innate immune function in a targeted organ to prevent and treat a wide range of diseases, including cancer, chronic inflammatory diseases, and infections. Designed to train innate immunity in a safe and targeted way, Qu has completed four Phase 2 studies and is initiating two new randomized placebo-controlled studies in immunosenescence and in post-operative immune suppression in late-stage colon cancer. Qu's platform has transformative potential across a range of important diseases. Contact: Hal Gunn <hal@qubiologics.com; Emilie Bouchard <ebouchard@qubiologics.com>
Rhythm Biotherapeutics Darryl Davis Rhythm Biotherapeutics is a pre-clinical stage biotechnology company developing exosome-based therapeutics to prevent and treat abnormal heart rhythms. Exosomes are therapeutic microparticles secreted by cells that repair atrial tissue to prevent atrial fibrillation and reduce the risk of stroke. Rather than wait to treat arrhythmias after they occur, Rhythm Biotherapeutics prevents the underlying inflammatory process that triggers post operative atrial fibrillation. Contact: Darryl Davis <darrylrdavis@gmail.com>
Roche Diagnostics Canada and University of Ottawa Heart Institute Peter Liu *rochecanada.com* Diagnostic biomarkers such as IGFBP7 for heart failure, vascular impairment, and cognitive impairment. Contact: Peter Liu <peter.liu@utoronto.ca>
Rogue Research Inc. Roch Comeau *rogue-research.com* Rogue Research was established 22 years ago and developed the Brainsight neuronavigator which assists over 1000 laboratories around the world with the use of non-invasive brain stimulation for human brain mapping, cognitive neuroscience as well as neurological and psychiatric research. We have evolved with our customers to include a next-generation transcranial magnetic stimulator and robotic positioner. This integrated solution will improve the quality of clinical trials and provide a viable path for widespread clinical deployment. Contact: Roch Comeau <roch@rogue-research.com>
Ruh Corp. Humeyra N. Celebi *ruhapp.io* Ruh is a mindfulness app. It integrates Islam and psychology with technology to promote mental well-being. We are seeking to evaluate the efficacy of our content through randomized controlled trials. Contact: Humeyra N. Celebi <humeyra@ruhapp.io>
Sinoveda Canada Inc. Yun K. Tam *sinoveda.com* Sinoveda is a drug discovery company focusing on developing combination drug therapies derived from botanicals. Using its AI assisted platform technology, SCI-2213, derived from a medical food, was developed. Preliminary experience in 24 human subjects showed that SCI-2213, after two days of treatment, is effective in alleviating 11 long COVID symptoms, which include cough, fatigue, brain fog, taste and smell Contact: Yun K. Tam <ytam@sinoveda.com>

Presenters and Exhibitors
St. Joseph's Healthcare Mackensey Bacon *research.stjoes.ca* The Research Institute of St Joe's supports high-impact research with fulsome, personalized solutions to clinical trial management including expert contract negotiation, finance planning and reporting, information technology infrastructure, quality assurance, knowledge mobilization, laboratory infrastructure including wet lab space and more. Our unique, collaborative approach, combines the talents of over 700 world-class clinical researchers and research support teams with the cutting-edge resources of St Joseph's Healthcare Hamilton. Together we support the growth of research and innovation within St. Joseph's Healthcare Hamilton and across the St. Joseph's Health System to improve the care of over 1 million members of our community each year. Contact: Mackensey Bacon <mbacon@stjosham.on.ca>
Syantra inc. Kristina Rinker *syantra.com* Syantra has a blood test for breast cancer detection (Syantra DX Breast Cancer) that is available on the market across Canada and provided through our CPSA accredited laboratory. The test is used as a part of the breast cancer screening process, is complementary to imaging, and has 92% accuracy. Contact: Kristina Rinker <tina.rinker@syantra.com>
TBI Finder Inc. Michael Noseworthy *tbifinder.com* TBIfinder is a data analytics company specializing in machine learning algorithms for personalized diagnostics of brain MRI scans. Whenever the brain "looks normal" on routine head MRI we are able to identify regions of both structural and functional abnormality and grade the severity of injury/disease. Using our MRI scanning protocol, doable on any 3T MRI, we can provide answers where previously there were none. Contact: Michael Noseworthy <nosewor@mcmaster.ca>
Tenomix Saumik Biswas *tenomix.com* Tenomix is a fast-growing medical technology startup that is targeting a serious problem in the colon cancer staging process: the manual lymph node search process. We have developed a novel platform technology (integrates robotics, ultrasound imaging & AI/ML) that will automate the existing manual lymph node search process in surgically removed colon cancer tissues, making the process less labour intensive, less costly, and more reliable for pathology laboratories, resulting in better informed treatment decisions for cancer patients. Contact: Saumik Biswas <saumik.biswas@tenomix.com>
Therapeutic Monitoring Systems (TMS) Andrew Seely *therapeuticmonitoring.com* TMS helps transform routine vital sign monitoring into valuable actionable clinical decision support, through the innovative patented combination of two novel technologies, variability analysis (analysis of patterns of variation of heart and lung rhythms) and artificial intelligence. We are introducing three novel software products, Extubation Advisor (first tool, Health Canada approval expected Q2/2023), Donation Advisor and Sepsis Advisor, that improve clinicians' capacity to determine optimal timing of a patient's safe liberation from the ventilator, determine a patient's candidacy for donation and transplantation after circulatory death and to determine where to admit a patient with infection (i.e. ward or intensive care unit). Contact: Andrew Seely <aseely@therapeuticmonitoring.com>

Presenters and Exhibitors
Trimedic Therapeutics Inc. Simon Jay *trimedictherapeutics.com* Trimedic identifies, licences, develops and commercializes pharmaceuticals and devices for the Canadian market. Presently, Trimedic is preparing to launch Sibboran (landiolol HCL for inj.), an anesthesia/intensive care product with important properties for addressing super ventricular tachycardias and related arrythmias. Contact: Douglas Hamilton <dhamilton@vasomune.com>; Simon Jay <simon@initiative3.com>
Vasomune Therapeutics, Inc. Shahid Ahmad *vasomune.com* Vasomune is a clinical stage Canadian biotechnology company developing a first-in-class vascular normalization investigational medicine targeting the Tie2 receptor. The Company's novel Tie2 agonist has multiple applications in which the underlying driver of mortality and morbidity is vascular endothelial instability, inflammation and vascular leak such a pneumonia/ARDS, sepsis, acute kidney injury and stroke/vascular dementia.
Vena Medical Michael Phillips *venamed.ca* Vena Medical is providing physicians with access to the future of stroke treatment by getting the clot out on the first try every time. Beginning with the Vena Balloon Distal Access Catheter which has improved First Pass Effect from 44% to 64%. Next will be the Vena MicroAngioscope, the world's smallest camera, capable of going inside veins and arteries to help physicians treat stroke. Contact: Michael Phillips <michael@venamed.ca>
VIBRAINT Inc Ilia Borishchev *vibraint.ai* VIBRAINT RehUp is a breakthrough brain-controlled rehabilitation robotics restoring mobility. Featuring a non-invasive brain-computer interface, VR and AI components, it was designed to assist paralyzed patients to regain movement - even in largely or totally immobilized limbs. Once approved by regulators, the system will be available on pay-by-use basis to rehabilitation clinics, centers and hospitals across North America. Contact: Ilia Borishchev <ib@vibraint.ai>
VitalTracer Azadeh Dastmalchi *vitaltracer.com* VitalTracer is focused on providing innovative personal healthcare products combining wearable technology and artificial Intelligence. We use biomedical sensors through the wrist/chest to measure vital signs continuously and store them in a secure cloud base environment that allows the patient to share them with their doctor or caregiver. Contact: Azadeh Dastmalchi <azadeh.dastmalchi@vitaltracer.com>
Xpan Inc. Zaid Atto *xpanmedical.com* Xpan is developing a miniaturized access port (trocar) for minimally invasive surgery (MIS), which can enter the body at a smaller, less invasive size than current standard devices before expanding to larger, desired sizes, with minimal tissue trauma. Contact: Zaid Atto <zaid@xpanmedical.com>

Presenters and Exhibitors
Zucara Therapeutics Inc. Michael Midmer *zucara.ca* Zucara Therapeutics is a Toronto based clinical stage company developing ZT-01, a first-in-class, once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with T1D and insulin-dependent Type 2 diabetes. The Company is planning a Phase 2 trial for ZT-01 after showing very compelling proof-of-concept in a Phase 1b trial last year in T1D patients. Zucara is interested in the support of the ACT Consortium to help advance clinical development for ZT-01 and expand into Type 2 diabetes as well as a long acting, weekly formulation, that would be more attractive to patients and commercial uptake. Contact: Michael Midmer <mmidmer@zucara.ca>